Background and rationale of the SU.FOL.OM3 study: Double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischeamic events in subjects with atherosclerosis in the coronary or cerebral arteries

Journal of Nutrition, Health and Aging

Volumn 7, Issue 6, 2003, Pages 428-435

  Galan, P ^a,b   De Bree, A ^a   Mennen, L ^a   Potier De Courcy, G ^a   Preziosi, P ^a   Bertrais, S ^a   Castetbon, K ^a   Hercberg, S ^a  

^a Bioinformatique et Chimie Moléculaire   (France)

^b INSERM   (France)

Author keywords

B vitamins; Cardiovascular diseases; Fish oil; Folate; N 3 fatty acids; Secondary intervention trial

Indexed keywords

CYANOCOBALAMIN; FISH OIL; FOLIC ACID; HOMOCYSTEINE; LIPOPROTEIN; OMEGA 3 FATTY ACID; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; BRAIN ARTERY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; FOLLOW UP; FRANCE; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIA; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 0141495170     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Haut Comité de la Santé Publique. Pour une politique nutritionelle de santé publique en France. 2000. Paris, Editions ENSP.
2. Guize L, Richard JL. De l'epidémiologie en cardiologie. Projections, la santé au futur 1990;2:127-34.
3. Roquebrune, J. P. Le livre de la prévention cardio-vasculaire. 1996. Paris, Fédération française de cardiologie.
4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
5. Refsum H, Ueland P, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med 1998;49:31-62.
6. Eikelboom JW, Lonn E, Genest J, Jr., Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
7. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
8. Ford ES. Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31:59-70.
9. Du Vigneaud V, Dyer HM, Harmon J. Growth-promoting properties of homocystine when added to cysteine-deficient diet and proof of structure of homocysteine. J Biol Chem 1933;101:719-26.
10. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
11. Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-6.
12. Malinow MR. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990;81:2004-6.
13. Genest JJ, Jr., McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
14. Ubbink JB, Vermaak WJ, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991;69:527-34.
15. Pancharuniti N, Lewis CA, Sauberlich HE et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
16. Wu LL, Wu J, Hunt SC et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-61.
17. Dalery K, Lussier Cacan S, Selhub J, Davignon J, Latour Y, Genest J, Jr. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 1995;75:1107-11.
18. Malinow MR, Ducimetiere P, Luc G et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27-34.
19. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease: The European concerted action project. JAMA 1997;277:1775-81.
20. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
21. Amesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
22. Stehouwer CDA, Weijenberg MP, van den BM, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men - A 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998;18:1895-901.
23. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med 1997;337:1632-3.
24. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998;29:2473-7.
25. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
26. Bots ML, Launer LJ, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44.
27. Kark JD, Selhub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med. 1999;131:321-30.
28. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-32.
29. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis - mechanisms for injury. Eur Heart J 2000;21:967-74.
30. Brown AA, Hu FB, Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 2001;73:673-86.
31. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 2000;130:369S-72S.
32. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995;10:111-3.
33. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
34. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
35. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20-65 y. Am J Clin Nutr 2001;73:1027-33.
36. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
37. Brouwer IA, Van Dusseldorp M, West CE et al. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in an dietary controlled trial. J Nutr 1999;129:1135-9.
38. Riddell LJ, Chisholm A, Williams S, Mann JI. Dietary strategies for lowering homocysteine concentrations. Am J Clin Nutr 2000;71:1448-54.
39. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid-an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
40. Ubbink JB. van der Merwe A, Vermaak WJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993-8.
41. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8.
42. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85-9.
43. Rasmussen K, Moller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996;42:630-6.
44. Woodside JV, Young IS, Yarnell JW et al. Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial. Atherosclerosis 1999;144:419-27.
45. Dierkes J, Kroesen M, Pietrzik K. Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res 1998;68:98-103.
46. den Heijer M, Brouwer IA, Bos GM et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-61.
47. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ., 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-41.
48. Stroes ES, van Faassen EE, Yo M et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-34.
49. Vermeulen EG, Rauwerda JA, Erix P et al. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature atherothrombotic cerebrovascular disease. A prospective cohort study. Neth J Med 2000;56:138-46.
50. de Jong SC, Stehouwer CD, van den BM, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J Intern Med 1999;246:87-96.
51. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 2000;13:105-10.
52. Vermeulen EGJ, Stehouwer CDA, Twisk JWR et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B-6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
53. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
54. Bostom AG, Garber C. Endpoints for homocysteine-lowering trials. Lancet 2000;355:511-2.
55. Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 2000;71:171S-5S.
56. Passmore R, Eastwood MA. Fats. In: Davidson GP, Passmore R, eds. Human nutrition and dietetics. Edinburg: Churchill Livingstone 1986:54-69.
57. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980;33:2657-61.
58. Dyerberg J, Bang HO. A hypothesis on the development of acute myocardial infarction in Greenlanders. Scand J Clin Lab Invest Suppl 1982;161:7-13.
59. Kromhout D, Bosschieter EB, de Lezenne CC. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-9.
60. Kromhout D, Feskens EJ, Bowles CH. The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 1995;24:340-5.
61. Rodriguez BL, Sharp DS, Abbott RD et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. The Honolulu Heart Program. Circulation 1996;94:952-6.
62. Daviglus ML, Stamler J, Orencia AJ et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997;336:1046-53.
63. Albert CM, Hennekens CH, O'Donnell CJ et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-8.
64. Oomen CM, Feskens EJ, Rasanen L et al. Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol. 2000;151:999-1006.
65. Hu FB, Bronner L, Willett WC et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002;287:1815-21.
66. Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH. Fish consumption and cardiovascular disease in the physicians health study: a prospective study. Am J Epidemiol. 1995;142:166-75.
67. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995;332:977-82.
68. Appleby PN, Thorogood M, Mann JI, Key TJ. The Oxford Vegetarian Study: an overview. Am J Clin Nutr 1999;70:525S-31S.
69. Jamrozik K, Broadhurst RJ, Forbes S, Hankey GJ, Anderson CS. Predictors of death and vascular events in the elderly: the Perth Community Stroke Study. Stroke 2000;31:863-8.
70. Vollset SE, Heuch I, Bjelke E. Fish consumption and mortality from coronary heart disease (letter). N Eng J Med 1985;313:821.
71. Salonen JT, Seppanen K, Nyyssonen K et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 1995;91:645-55.
72. Dolecek TA, Grandits G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial. World Rev Nutr Diet 1991;66:205-16.
73. Pietinen P, Ascherio A, Korhonen P et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol. 1997;145:876-87.
74. Schwartz SM, Siscovick DS, Malinow MR et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-7.
75. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65:1645S-54S.
76. von Schacky C. n-3 fatty acids and the prevention of coronary atherosclerosis. Am J Clin Nutr 2000;71:224S-7S.
77. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000;71:202S-7S.
78. Nair SS, Leitch JW, Falconer J, Garg ML. Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action. J Nutr 1997;127:383-93.
79. Kang JX, Leaf A. The cardiac antiarrhythmic effects of polyunsaturated fatty acid. Lipids 1996;31 Suppl:S41-S44.
80. Morris MC, Taylor JO, Stampfer MJ, Rosner B, Sacks FM. The effect of fish oil on blood pressure in mild hypertensive subjects: a randomized crossover trial. Am J Clin Nutr 1993;57:59-64.
81. Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61.
82. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.
83. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival. Cardiovasc Drugs Ther 1997;11:485-91.
84. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
85. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 2000;26:341-8.
86. Fohr IP, Prinz-Langenohl R, Bronstrup A et al. 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate of folic acid in healthy young women. Am J Clin Nutr 2002;75:275-82.
87. Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. Unmetabolized folic acid in serum: Acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997;65:1790-5.
88. Hill C, Com-Nougué C, Kramar A et al. Analyse statistique des données de survie. In: Schwarts D, ed. Paris: INSERM, Medicin Sciences/Flammarion 1996.
89. Hercberg S, Galan P, Preziosi P et al. Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. SUpplementation en VItamines et Mineraux AntioXydants Study. Int J Vitam Nutr Res 1998;68:3-20.
90. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71:614S-20S.
91. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.